FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis

Cancer cells balance with the equilibrium of cell death and growth to expand and metastasize. The activity of mammalian sterile20-like kinases (MST1/2) has been linked to Apoptosis and tumor suppression via YAP/Hippo pathway-independent and -dependent mechanisms. Using a kinase substrate screen, we identified here MST1 and MST2 among the top substrates for Fibroblast Growth Factor receptor 4 (FGFR4). In COS-1 cells, MST1 was phosphorylated at Y433 residue in an FGFR4 kinase activity-dependent manner, as assessed by mass spectrometry. Blockade of this phosphorylation by Y433F mutation induced MST1 activation, as indicated by increased threonine phosphorylation of MST1/2, and the downstream substrate MOB1, in FGFR4-overexpressing T47D and MDA-MB-231 breast Cancer cells. Importantly, the specific knockdown or short-term inhibition of FGFR4 in endogenous models of human HER2⁺ breast Cancer cells likewise led to increased MST1/2 activation, in conjunction with enhanced MST1 nuclear localization and generation of N-terminal cleaved and autophosphorylated MST1. Unexpectedly, MST2 was also essential for this MST1/N activation and coincident Apoptosis induction, although these two kinases, as well as YAP, were differentially regulated in the breast Cancer models analyzed. Moreover, pharmacological FGFR4 inhibition specifically sensitized the HER2⁺ MDA-MB-453 breast Cancer cells, not only to HER2/EGFR and Akt/mTOR inhibitors, but also to clinically relevant Apoptosis modulators. In TCGA cohort, FGFR4 overexpression correlated with abysmal HER2⁺ breast carcinoma patient outcome. Therefore, our results uncover a clinically relevant, targetable mechanism of FGFR4 oncogenic activity via suppression of the stress-associated MST1/2-induced Apoptosis machinery in tumor cells with prominent HER/ERBB and FGFR4 signaling-driven proliferation.